Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02527434 · ClinicalTrials.gov registry record · Phase 2
Study of Tremelimumab in Patients With Advanced Solid Tumors
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT02527434 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 64 participants.
The verdict
NCT02527434, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors
Interventions
- BIOLOGICAL Tremelimumab monotherapy
- BIOLOGICAL MEDI4736 monotherapy
- BIOLOGICAL MEDI4736 + tremelimumab combination therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-11-02 |
| Est. Completion | 2023-03-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02527434
The ClinicalTrials.gov registry entry for NCT02527434 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tremelimumab monotherapy is the first listed.
NCT02527434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02527434 about?
NCT02527434 is a clinical study titled "Study of Tremelimumab in Patients With Advanced Solid Tumors". A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors
What is the current status of trial NCT02527434?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2015-11-02. Estimated completion is 2023-03-28.
What interventions are being tested in trial NCT02527434?
The interventions under investigation include: Tremelimumab monotherapy (BIOLOGICAL), MEDI4736 monotherapy (BIOLOGICAL), MEDI4736 + tremelimumab combination therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT02527434?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.